-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On December 16, the official website of China's National Food and Drug Administration (NMPA) announced that Hausen Pharmaceuticals' third-generation EGFR-TKI Ametinib had been approved for a new indication
Image source: NMPA official website
Ametinib is a third-generation EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor) developed by Hausen Pharmaceuticals
In May 2021, the marketing application for new indications of Ametinib was included in the priority review by CDE
Image source: CDE official website
According to a press release issued by Hausen Pharmaceuticals, the company is currently exploring many new indications for Ametinib, including targeted combination chemotherapy, targeted anti-vascular therapy, and so on
Note: The original text has been deleted
Reference materials:
[1] Information to be obtained for the drug approval certificate issued by the National Medical Products Administration of China on December 16.